Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03063892

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Hip Fractures Femoral Fractures Fractures, Bone Hip Injuries Leg Injuries Wounds and Injuries

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

ProMedica Toledo Hospital

Toledo, Ohio, 43606, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over the age of 60 years
  • Hip fracture requiring surgical intervention
  • Signs consent and agrees to participate

Exclusion criteria

  • Under the age of 60
  • Does not sign consent or refuses participation
  • Known hypersensitivity to tranexamic acid
  • Multiple acute fractures
  • Creatinine clearance <30
  • History of seizures
  • Active hormone therapy
  • History of coagulation abnormality
  • History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE
  • Myocardial infarction (MI) and/or stents within the past year
  • History of intracranial hemorrhage
  • Acquired defective color vision
  • Patients admitted directly to nursing units or surgery without stay in the Emergency Center
  • Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital

Treatment and study plan

Tranexamic acid (TXA)

Drug

Tranexamic acid is an antifibrinolytic used to control bleeding

Other names: Cyklokapron

Saline Solution

Drug

Saline solution is used as the placebo comparator

Other names: normal saline

Primary outcomes

  1. proportion of patients requiring packed Red Blood Cell transfusion

    Time frame: 72 hours

    units, perioperative

Secondary outcomes

  1. intraoperative blood loss

    Time frame: 24 hours

    mL

  2. postoperative anemia

    Time frame: 72 hours

    Hgb <7g/dL

Sponsors and collaborators

Lead sponsor

Gregory M Georgiadis MD

Other

Registry information

Official study title

Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients

Important dates

Study start
2017
Primary completion
2027
Study completion
2027
First posted
Feb 24, 2017
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.